Hybrid UV-Vis/MS Assay for Free Cysteine Determination in Monoclonal Antibodies

Importance of the Topic

The control and measurement of free cysteine residues in monoclonal antibodies (mAbs) is critical for biopharmaceutical quality, stability, and functionality. Unpaired or solvent-exposed cysteines can arise from mispaired disulfides or partial reduction during cell culture and downstream processing, increasing aggregation risk and altering biological activity. Accurate quantification of reactive thiols and site-specific identification of modified cysteines support comparability studies, process control, and development of antibody–drug conjugates where cysteine accessibility governs conjugation efficiency and drug-to-antibody ratio.

Objectives and Study Overview

This application note presents a hybrid analytical workflow that combines a spectrophotometric Ellman (DTNB) assay measured on the Agilent Cary 3500 Multicell UV-Vis spectrophotometer with high-resolution LC/Q-TOF mass spectrometry on an Agilent 6545XT AdvanceBio LC/Q-TOF. The combined aim is to (1) quantify total reactive free thiols in mAbs and (2) confirm the number and location of cysteines labeled by the DTNB-derived 2-nitro-5-thiobenzoic acid (TNB) adduct. The workflow is demonstrated on innovator and biosimilar rituximab products in native and partially reduced states.

Methodology and Instrumentation

The experimental approach consists of two complementary steps: a colorimetric DTNB assay for bulk thiol quantitation and LC/Q-TOF MS for chain-resolved, site-specific characterization of TNB labeling.

Key methodological points:

• Sample preparation: mAb stocks (10 mg/mL) were diluted to 5 mg/mL in 0.1 M sodium phosphate buffer (pH 8.0) with 1 mM EDTA. Partial reduction was induced using TCEP at a final concentration of 10 mM and incubated 4 hours at room temperature.
• DTNB (Ellman) assay: DTNB solution (~10 mM) was reacted with samples; absorbance at 412 nm was measured on the Cary 3500 Multicell UV-Vis. Calibration standards of L-cysteine (0.25–1.5 mM) were measured simultaneously across multiple cuvettes to generate a linear standard curve (R2 ≥ 0.999).
• Data analysis for DTNB: The absorbance at 412 nm and the standard curve were used to calculate free sulfhydryl-to-protein molar ratios (free‑SH:protein) to quantify thiol content in native and reduced samples.
• LC/Q-TOF MS: DTNB-reacted, reduced samples were analyzed after spin filtration on an Agilent 1290 Infinity II Bio-LC with a PLRP-S reversed-phase column. Mass spectra were acquired on the Agilent 6545XT AdvanceBio LC/Q-TOF and processed using Agilent MassHunter software to deconvolute intact heavy and light chain masses and to resolve TNB-modified species and glycoforms.

Used Instrumentation

• Agilent Cary 3500 Multicell UV-Vis Spectrophotometer with ultra-microvolume rectangular cells (10 mm pathlength, 70 µL fill volume), Cary UV Workstation software.
• Agilent 1290 Infinity II Bio-LC (pump, multisampler, multicolumn thermostat) with Agilent PLRP-S column (2.1 × 50 mm, 5 µm).
• Agilent 6545XT AdvanceBio LC/Q-TOF MS with dual AJS ESI source; data acquisition and analysis with Agilent MassHunter (Qualitative Analysis, BioConfirm).

Main Results and Discussion

DTNB assay results:

• The multicell Cary 3500 produced a highly linear cysteine calibration across 0.25–1.5 mM (R2 ≈ 0.999), enabling precise quantitation of free thiols. The characteristic DTNB absorbance peak at 412 nm and an isosbestic point near 357 nm were used to verify assay stoichiometry and performance.
• Native mAbs showed very low free‑SH:protein ratios (0.06–0.14 mol/mol), consistent with intact disulfide bonding. Partially reduced samples exhibited substantially higher ratios (6.6–10.3 mol/mol), reflecting exposure of multiple cysteine residues upon controlled reduction.

LC/Q-TOF MS findings:

• Deconvoluted intact-chain spectra identified TNB-labeled species on both light and heavy chains. For reduced samples, a reproducible pattern emerged: one TNB label on the light chain and three on the heavy chain per chain set (i.e., four reactive cysteines per mAb half, corresponding to eight reactive cysteines per intact antibody), matching DTNB quantitation.
• MS resolved glycoform heterogeneity on heavy chains (G0F, G1F, G2F) and showed multiple TNB conjugation states combined with these glycoforms.
• The combined data demonstrated that controlled partial reduction selectively exposes a defined subset of interchain cysteines for DTNB reaction while preserving intrachain disulfides, providing both quantitative (bulk thiol counts) and structural (site-specific labeling) evidence of reactive cysteine locations.

Benefits and Practical Applications of the Method

The hybrid UV-Vis/MS workflow provides complementary capabilities: rapid, high-throughput quantitation of total reactive thiols by DTNB and orthogonal structural confirmation by high-resolution MS. Practical benefits include:

• Robust QC metric for manufacturing and comparability studies to detect changes in thiol exposure.
• Support for ADC development by identifying accessible cysteines and informing conjugation strategies and DAR control.
• Ability to correlate process-induced partial reduction with specific cysteine accessibility, aiding process optimization to minimize undesired modifications or aggregation.

Future Trends and Potential Uses

Extensions and future directions for this workflow include:

• Integration with peptide mapping or native MS approaches to assign reactivity to specific sequence positions and local structural contexts with higher resolution.
• Automation and in-line coupling of spectroscopic assays with LC/MS for faster, higher-throughput screening during process development.
• Application to other cysteine-containing biologics and engineered antibody formats where noncanonical cysteines or engineered conjugation sites are used.
• Combining this approach with orthogonal redox or alkylation chemistries to probe disulfide bond dynamics and reversible cysteine modifications.

Conclusion

The described hybrid assay combining the Cary 3500 UV-Vis DTNB quantitation with Agilent 6545XT LC/Q-TOF MS structural confirmation provides a reliable, complementary platform for measuring free cysteines in mAbs. The DTNB assay delivers precise bulk thiol measurements with the throughput advantage of multicell acquisition, while LC/Q-TOF MS confirms the number and distribution of TNB-labeled cysteines and resolves glycoform contributions. Together, these data enable confident assessment of thiol reactivity relevant to product quality, comparability, and conjugation design.

References

1. Liu H., May K. Disulfide Bond Structures of IgG Molecules: Structural Variations, Chemical Modifications and Possible Impacts to Stability and Biological Function. MAbs 2012, 4(1), 17–23.
2. Banks D. D., Gadgil H. S., Pipes G. D., et al. Removal of Cysteinylation from an Unpaired Sulfhydryl in the Variable Region of a Recombinant Monoclonal IgG1 Antibody Improves Homogeneity, Stability, and Biological Activity. J. Pharm. Sci. 2008, 97(2), 775–790.
3. Trexler‑Schmidt M., Sargis S., Chiu J., et al. Identification and Prevention of Antibody Disulfide Bond Reduction During Cell Culture Manufacturing. Biotechnol. Bioeng. 2010, 106(3), 452–461.
4. Furuki K., Toyo'oka T. Determination of Thiol-to-Protein Ratio and Drug-to-Antibody Ratio by In-Line Size Exclusion Chromatography with Post-Column Reaction. Anal. Biochem. 2017, 527, 33–44.
5. Abdollahpour‑Alitappeh M., Lotfinia M., Razavi‑Vakhshourpour S., et al. Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates. Iran Biomed. J. 2017, 21(4), 270–274.